Drug Profile
Sirolimus - Veloxis Pharmaceuticals
Alternative Names: LCP-SiroLatest Information Update: 30 Dec 2021
Price :
$50
*
At a glance
- Originator LifeCycle Pharma
- Developer Veloxis Pharmaceuticals
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Transplant rejection
Most Recent Events
- 07 Jun 2011 Sirolimus - LifeCycle Pharma is still available for licensing (http://www.lifecyclepharma.com/)
- 29 Nov 2007 Phase-I clinical trials in Autoimmune disorders in Denmark (PO)
- 29 Nov 2007 Phase-I clinical trials in Transplant rejection in Denmark (PO)